Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

In the fourth quarter of 2024, Novo Nordisk reported strong performance across its GLP-1 portfolio. Ozempic and Rybelsus, the oral formulation of semaglutide, exceeded consensus expectations.

In the fourth quarter of 2024, Novo Nordisk reported strong performance across its GLP-1 portfolio. Ozempic and Rybelsus, the oral formulation of semaglutide, exceeded consensus expectations. While ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

Shares in Novo Nordisk were up nearly 12 ... after the revelation that Wegovy, Ozempic, and another semaglutide-based diabetes therapy called Rybelsus have been included on the list of the next ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

NAION is a very rare eye disease, and it's not an adverse drug reaction listed on the labels for semaglutide in the form of Ozempic, Rybelsus and Wegovy, Novo Nordisk said in a statement.

RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...